Condition: Hepatic Impairment (HI) · Sponsor: Edgewise Therapeutics, Inc.
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.
This description comes directly from the study's public registry record.
Edgewise Therapeutics, Inc. · 720-262-7002 · cardiacstudies@edgewisetx.com
Always discuss trial participation with your own doctor first.
| The University of Miami Division of Clinical Pharmacology | Miami, Florida, United States | Recruiting |
| Orlando Clinical Research Center | Orlando, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07324616